• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Upcoming dvm360 Conferences
Resources
CBD in Pets
CE Requirements by State
Contests
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
Veterinary Heroes
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

New drugs in dermatology (Proceedings)

August 1, 2011
.Patrick Hensel, Dr.med.vet., DACVD

In the field of veterinary medicine we see a constant search for newer, more effective, and convenient but inexpensive drugs with lesser side effects. Not only new drugs are interesting, but old drugs are occasionally rediscovered for new indications.

In the field of veterinary medicine we see a constant search for newer, more effective, and convenient but inexpensive drugs with lesser side effects. Not only new drugs are interesting, but old drugs are occasionally rediscovered for new indications. Although many of the new approved drugs available have been thoroughly investigated, reports of the use of older drugs or the use of newer drugs for a different indication are often based on anecdotal reports and need to be further investigated in controlled studies.

Cefovecin sodium (Convenia® Pfizer; 80 mg/ml)

     • This is a semi-synthetic cephalosporin with bactericidal effect which inhibits bacterial cell wall syntheses and is relatively resistant to bacterial beta-lactamases. Its main antibacterial spectrum is: gram-negative bacteria (E. coli, Proteus, Klebsiella), gram-positive bacteria (Staphylococci & Streptococci.). Cefpodoxime is not effective against Pseudomonas aeruginosa, Enterococci and methicillin-resistant Staph. Poor efficacy has been shown against anaerobes.

     • Indication

          o Dogs: skin infections (pyoderma, wounds, abscesses) with Staphylococcus intermedius and Streptococcus canis

          o Cats: infections with Pasteurella multocida

     • Occasional GI signs (vomiting, diarrhea) may be seen.

     • Dosage: 8 mg/kg subcutaneous. Injection can be repeated after 7 to 14 days (very convenient!)

Cefpodoxime proxetil (Simplicef® Pfizer; 100 mg, 200 mg)

     • This 3rd generation cephalosporin (antimicrobial activity, see Cefovecin)

     • Indication: skin infections (pyoderma, wounds, abscesses) in dogs.

Advertisement

     • Drug is well tolerated. Occasionally GI signs may occur.

     • Dosage: 5-10 mg/kg orally every 24 hours

Chloramphenicol (Duricol®; 50 mg, 100 mg or Viceton®; 250 mg, 500 mg)

     • Broad spectrum antibiotic inhibiting bacterial protein synthesis. Gram-positive aerobic organisms (Streptococci, Staphylococci) are generally susceptible, and many anaerobic bacteria (Clostridium, Bacteroides, Fusobacterium) and organisms such as Nocardia, Mycoplasma, and Rickettsia are sensitive to chloramphenicol.

     • Indication: methicillin-resistant Staph. spp. infections

     • Usually well tolerated but dose-related bone marrow suppression (reversible) is occasionally seen with longterm use, as well as GI signs.

     • Dosage: 30-50 mg/kg orally every 8 hours

     • Caution: Can cause irreversible anaplastic anemia in humans!

Cyclosporine (Atopica® Novartis; 25 mg, 50 mg, 100 mg; Neoral®; 100 mg/ml)

     • CsA is a naturally produced (fungus: Tolypocladium inflatum) calcineurin inhibitor with anti-inflammatory and immunosuppressive properties focused on cell-mediated immune response.

     • Indication: Perianal fistula, canine atopic dermatitis; may also be used for maintenance of auto-immune diseases (e.g. pemphigus foliaceus)

     • Since CsA is mainly metabolized through the liver it should be used with caution in patients with liver disease. Many drugs are metabolized through the same cytochrome P450 enzyme system and are able to reduce the metabolism of CsA. The use of ketoconazole at 5 mg/kg orally per day may help to reduce the CsA dose by up to 50%.

     • The most common side effects are vomiting, anorexia and diarrhea.

     • Dosage: 5 mg/kg orally every 24 hours

Tacrolimus (Protopic®; 0.1% or 0.3% ointment)

     • This is a topical calcineurin inhibitor with similar mechanism as cyclosporine. Advantage of calcineurin inhibitors compared to steroids is their lack of cutaneous atrophy and metabolic effects.

     • Indication: localized atopy, discoid lupus erythematosus (DLE), pemphigus erythematosus (PE), pemphigus foliaceus (PF), cutaneous idiopathic vasculitis, alopecia areata, Vitiligo. May be also used for maintenance of perianal fistula.

     • Increased erythema and irritation can occasionally be observed after starting therapy, but the reaction is transient.

     • Dosage: apply daily on affected skin area.

Imiquimod (Aldara®; 5% cream)

     • Imiquimod is an immune response modifier which is supposed to stimulate the patient's own immune system to release a variety of cytokines including interferon-alpha and interleukin-12. It does not have direct anti-viral effect, but the drug activates monocytes and macrophages to release cytokines that induce regression in viral protein production.

     • Indication: feline herpes virus dermatitis, actinic keratosis, squamous cell carcinoma and Bowen's disease, and viral papilloma.

     • Localized irritation and pruritus can occur.

     • Dosage: apply once daily to twice weekly on affected skin area.

Trilostane (Vetoryl® Dechra; 30 mg, 60 mg)

     • Trilostane is a synthetic steroid analog that acts as a competitive inhibitor of 3-beta hydroxysteroid dehydrogenase, thereby reducing synthesis of cortisol, aldosterone, and adrenal androgens. Inhibition is reversible and dose dependent.

     • Trilostane significantly reduces synthesis of progesterone and should not be used in pregnancy.

     • The drug is usually well tolerated. Mild lethargy, electrolyte changes, and inappetence can occur initially.

     • Indication: pituitary-dependent or adrenal-dependent hyperadrenocorticism, Alopecia X.

     • Dosage: 2-20 mg/kg orally once daily with food. Monitor with ACTH-stim test, serum electrolytes (hyperkalemia), and adjust dose based on clinical response.

Spinosad/Milbemycin oxime (Trifexis® Elanco)

     • Activates the nicotinic acetylcholine receptors of the flea, resulting in paralysis and death. Kills up to 100% adult fleas within 4 hours.

     • Side effects: a few reports of ivermectin toxicity if given in combination with off-label use daily oral ivermectin to treat generalized demodicosis. Should not be given to puppies <8 weeks of age.

     • Indication: Flea bite hypersensitivity; for dogs only. Adult fleas, heartworm, intestinal parasites (roundworm, whipworm, hookworm).

Imidacloprid/Moxidectin (Advantage Multi™ Bayer)

     • Imidacloprid is a neonicotinoid, which is absorbed upon contact with the flea through the intersegmental membranes. It acts as an agonist on the postsynaptic nicotinic acetylcholine receptors of motor neurons in insects. Imidacloprid is an adulticide and a larvicide. Moxidectin binds to receptors on neuronal membranes of nematodes and muscle membranes of arthropods, causing increased permeability and an influx of chloride ions → hyperpolarization → paralysis → death of parasite. Has also agonist activity at the GABA receptor complex of nematodes and arthropods.

     • Indication:

          o Imidacloprid: fleas

          o Moxidectin: adult nematodes, developmental stages of filarial nematodes (heartworms), mites

     • Dosage: once monthly for flea and heartworm prevention, twice monthly for the treatment of mite (e.g. Sarcoptes) infestation. Weekly application may be effective for the treatment of generalized demodicosis.

Doramectin (Dectomax® Pfizer)

     • A FDA approved large animal injectable antiparasitic drug, which has been used effectively in the treatment of generalized demodicosis in dogs at a dose of 0.6mg/kg SC once weekly. In the initial studies no increased side effects were noticed. However, it is not recommended to use this drug in ivermectin-sensitive animals.

Interferon alpha 2b (MWI Veterinary Supply)

     • Viral infections are known to trigger the production of cytokines, which are synthesized and secreted in response to viral infection, resulting in the inhibition of viral replication. It is also used for immunomodulatory purposes.

     • Indication in cats: indolent ulcers, idiopathic facial dermatitis, dermatitis secondary to FHV infection, and atopy. Dogs: Canine Papilloma Virus (30-20,000 IU orally daily)

Related Content:

Dermatology
Comparing treatments for restoring the skin barrier in atopic dogs
Comparing treatments for restoring the skin barrier in atopic dogs
Exploring molecular allergology as the future of allergy testing and immunotherapy
Exploring molecular allergology as the future of allergy testing and immunotherapy
dvm360® is seeking nominations for the 2023 Veterinary Heroes Awards
dvm360® is seeking nominations for the 2023 Veterinary Heroes Awards

Advertisement

Latest News

Vermont emergency veterinary clinic now offers exotic animal care

Comparing treatments for restoring the skin barrier in atopic dogs

Increasing efficiency and productivity in uncertain times

AAVMC awards almost $100,000 in diversity scholarships

View More Latest News
Advertisement